Endra Life Sciences (NDRA) Fundamental Analysis: Revenue, Earnings & Valuation

0.81 / 10

Underperform

Fundamental rating is Underperform with a 0.8/10 quality score. Profit‑MV is the only positive factor; Revenue‑MV and Cash‑MV are negative. Overall fund score is 0.81, indicating inadequate earnings, cash and asset metrics, leading to a weak financial profile.

Analysis Checks(1/10)

Revenue-MV

Value-0.28

Score0/3

Weight14.38%

1M Return-4.18%

ROA (%)

Value-120.26

Score0/3

Weight15.88%

1M Return-6.58%

Net cash flow from operating activities / Operating revenue (%)

Value-1498.12

Score0/3

Weight15.92%

1M Return-6.63%

Profit-MV

Value0.40

Score2/3

Weight-13.58%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-160.35

Score0/3

Weight15.88%

1M Return-6.58%

EBIT / Total operating revenue (%)

Value-3027.80

Score0/3

Weight15.92%

1M Return-5.19%

Asset-MV

Value-0.49

Score1/3

Weight-1.45%

1M Return0.38%

Net profit / Total operating revenue (%)

Value-2142.43

Score0/3

Weight16.21%

1M Return-6.68%

Cash-MV

Value-0.09

Score1/3

Weight12.87%

1M Return-4.16%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight7.95%

1M Return-2.39%

Is NDRA fundamentally strong?

NDRA scores 0.81/10 on fundamentals and holds a Premium valuation at present. Backed by its -282.47% ROE, 0.00% net margin, -0.58 P/E ratio, 29.61 P/B ratio, and 111.09% earnings growth, these metrics solidify its Underperform investment rating.